Blockbuster Drugs on Patent Cliffs Market is expected to reach USD 148 billion by 2034

Market Overview
The Blockbuster Drugs on Patent Cliffs Market represents one of the most strategically significant transitions in the global pharmaceutical industry. A patent cliff occurs when exclusivity on a high-revenue drug expires, allowing generic or biosimilar competitors to enter the market, resulting in steep revenue declines for the original manufacturer and large opportunities for generic and biosimilar producers.

Between 2024 and 2030, over USD 258 billion worth of top-selling branded drugs will lose patent protection. This includes major therapies across oncology, diabetes, immunology, cardiovascular diseases, respiratory therapy, and rare diseases.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/73666

The global opportunity for generics and biosimilars arising from these patent expiries is expected to reach USD 148 billion by 2034, growing at a 7.1% CAGR.

Key Market Drivers
• Large Wave of Patent Expiries: Multiple blockbuster biologics and small molecules are set to lose exclusivity in the next 5-7 years.
• Rapid Biosimilar Uptake: Strong demand for cost-effective biologics in oncology, immunology, and metabolic diseases.
• Increasing Global Healthcare Cost Pressure: Governments and insurers aggressively promote generics and biosimilars to reduce spending.
• Expansion of Low-Cost Manufacturing: Emerging markets are expanding capabilities to supply global generics and biosimilars.
• High Number of Specialty Pharma Entrants: Mid-size companies and CDMOs are entering the high-value biosimilar space.
• R&D Diversification by Big Pharma: Pharma companies are restructuring pipelines to offset expected revenue losses.

Market Challenges
• Regulatory Complexity for Biosimilars: Approval pathways remain stringent, especially in the U.S.
• Legal Battles: Patent litigations and secondary patents delay market entry.
• Manufacturing Barriers for Biologics: Biosimilar production requires advanced bioprocessing capability.
• Brand Loyalty for Chronic Therapies: Some patients and physicians demonstrate reluctance to switch.
• Intense Price Competition: Generic markets face price erosion and margin pressure.

Drugs Approaching Patent Cliffs (2024-2030)
(Values represent recent peak yearly sales)
Major Biologics
• Keytruda (Merck): >USD 23B
• Opdivo (BMS): >USD 9B
• Stelara (J&J): >USD 10B
• Eylea (Regeneron): >USD 9B
• Cosentyx (Novartis): >USD 7B
• Darzalex (J&J): >USD 8B
• Ibrance (Pfizer): >USD 5B

Small Molecule Blockbusters
• Eliquis (BMS/Pfizer): >USD 12B
• Xarelto (Bayer/J&J): >USD 6B
• Ozempic (Novo Nordisk) - LOE early 2030s
• Januvia (Merck): >USD 3B
• Xtandi (Pfizer/Astellas): >USD 5B

Therapeutic Areas Most Impacted
• Oncology
• Immunology
• Diabetes & Metabolic Conditions
• Cardiovascular Disease
• Ophthalmology
• Respiratory Diseases
• Rare/Orphan Conditions

Market Segmentation
By Drug Type
• Biologics on Patent Cliff
• Small Molecules on Patent Cliff
• Biosimilars
• Generics

By Therapeutic Area
• Oncology (largest share)
• Immunology
• Endocrinology
• Cardiovascular
• Respiratory
• Gastroenterology
• CNS Disorders
• Rare Diseases

By Molecule Type
• Monoclonal Antibodies
• Recombinant Proteins
• Peptides
• Small Molecule APIs

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By End User
• Pharmaceutical Companies
• Biosimilar Manufacturers
• Generic Drug Companies
• CDMOs
• Healthcare Providers
• Payers & Insurance Companies

Explore Full Report here: https://exactitudeconsultancy.com/reports/73666/blockbuster-drugs-on-patent-cliffs-market

Regional Insights
North America
• The U.S. is the most lucrative market for post-patent opportunities.
• Biosimilar adoption is accelerating due to payer pressure.
• Major biologics such as Keytruda and Stelara will heavily impact the U.S. market.
Europe
• Europe leads in biosimilar penetration, especially in Germany, France, the UK, Italy, and the Nordics.
• Strong regulatory framework and centralized EMA approvals support rapid uptake.
Asia Pacific
• Fastest-growing region due to:
o Cost advantages
o Expanding biologics manufacturing
o Large generic industry in India
o Growing biosimilar capacity in South Korea and China
• APAC will be the largest supplier of global biosimilars.
Latin America
• Increasing generic spending by public health systems.
• Local manufacturers are expanding API and biosimilar capabilities.
Middle East & Africa
• Slower adoption but improving due to expanding universal healthcare coverage.

Competitive Landscape - Key Companies
Biologics Innovators Impacted:
1. Merck
2. Bristol-Myers Squibb
3. Novartis
4. Johnson & Johnson
5. Roche
6. Regeneron
7. Pfizer
8. AstraZeneca
9. Amgen
10. AbbVie

Leading Biosimilar & Generic Producers:
1. Sandoz
2. Teva Pharmaceuticals
3. Viatris (Mylan)
4. Biocon Biologics
5. Samsung Bioepis
6. Celltrion
7. Amneal Pharmaceuticals
8. Dr. Reddy's Laboratories
9. Cipla
10. Sun Pharma

Major CDMOs Supporting LOE Manufacturing:
• Lonza
• Catalent
• WuXi Biologics
• Thermo Fisher
• Fujifilm Diosynth

Recent Developments
• Increasing biosimilar launches for oncology and immunology biologics.
• Major pharma companies restructuring R&D to mitigate revenue loss.
• Growth of patent settlement agreements that define entry timing for generic/biosimilar competitors.
• Rapid increase in global filers for high-value molecule biosimilars.
• Several emerging markets accelerating regulatory approval timelines.

Opportunities
• Development of first-to-file generics for multi-billion-dollar drugs.
• Expansion of biosimilar pipelines for monoclonal antibodies and fusion proteins.
• Investment in high-value CDMO biologics manufacturing.
• Rapid growth in oncology biosimilars for PD-1/PD-L1 inhibitors.
• Lifecycle management strategies for innovator companies (formulations, combinations, new indications).
• Partnerships between innovators and biosimilar companies to manage market share transitions.

Conclusion
The Blockbuster Drugs on Patent Cliffs Market represents one of the largest shifts in the global pharmaceutical ecosystem. With USD 258 billion in branded drug revenue set to lose exclusivity by 2030, the next decade will see massive opportunities for generics and biosimilars while pushing innovator companies to reinvent their pipelines.

Companies that focus on biosimilar development, cost-efficient manufacturing, strategic partnerships, and early planning for LOE products will be the major beneficiaries of this multibillion-dollar transition.

This report is also available in the following languages : Japanese (特許崖市場で大ヒット医薬品), Korean (특허 절벽 시장의 블록버스터 약물), Chinese (专利悬崖上的重磅药物市场), French (Médicaments à succès sur le marché des brevets expirés), German (Blockbuster-Medikamente auf dem Markt für auslaufende Patente), and Italian (Farmaci di successo sul mercato dei brevetti), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/request-sample/73666

Our More Reports:

Charcot-Marie-Tooth Disease Market
https://exactitudeconsultancy.com/reports/34975/charcot-marie-tooth-disease-market

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market
https://exactitudeconsultancy.com/reports/35075/chemotherapy-induced-nausea-and-vomiting-cinv-drugs-market

Osteoarthritis Treatment Market
https://exactitudeconsultancy.com/reports/35403/osteoarthritis-treatment-market

Animal Pharmaceuticals Market
https://exactitudeconsultancy.com/reports/40922/animal-pharmaceuticals-market-segmentation-by-product-type-antibiotics-vaccines-anti-parasitic-ant

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.